News & Updates
Filter by Specialty:
First-line use of dual immunotherapy in a patient with unresectable HCC
A 55-year-old male was diagnosed with localized hepatocellular carcinoma (HCC) in 2009. Over the next 10 years, he had multiple episodes of disease recurrence, which were managed with surgical resection and locoregional therapy such as ablation or transarterial chemoembolization.
First-line use of dual immunotherapy in a patient with unresectable HCC
08 Aug 2024
Cabozantinib and SBRT: Two feasible post-IO strategies in HCC
Liver cancer is a major cause of death globally and in Hong Kong. Both first- and second-line treatment of the disease have evolved considerably over recent years, following the approval of immune checkpoint inhibitors (ICIs). At present, over half of hepatocellular carcinoma (HCC) patients require second-line treatment, yet data on therapies administered after immunotherapy are lacking. This article summarizes locally reported findings on use of cabozantinib and stereotactic body radiotherapy (SBRT) in HCC patients who progressed on immunotherapy.
Cabozantinib and SBRT: Two feasible post-IO strategies in HCC
07 Aug 2024
Cervical cancer, leukaemia survivors face heightened risks during pregnancy
Pregnancies in women who have survived cervical cancer or leukaemia should be considered high-risk due to the potential for multiple severe obstetric complications, as reported in a study.
Cervical cancer, leukaemia survivors face heightened risks during pregnancy
06 Aug 2024
KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer
Perioperative pembrolizumab plus chemotherapy confers survival benefit in individuals with locally advanced gastric and gastroesophageal junction (G/GEJ) cancer in the final analysis of the phase III KEYNOTE-585 trial.
